ACET Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Adicet Bio Inc (ACET) is not a strong buy at this time for a beginner investor with a long-term focus and $50,000-$100,000 to invest. The stock lacks significant positive catalysts, has weak financial performance, and no clear trading signals. The technical indicators suggest a neutral to bearish trend, and the absence of recent news or strong institutional interest further diminishes its appeal.
The MACD is positive and expanding, indicating slight bullish momentum. However, the RSI is neutral at 53.71, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Key support and resistance levels are at Pivot: 7.048, R1: 7.495, S1: 6.601, R2: 7.771, and S2: 6.325, suggesting limited upside potential.
The MACD is showing slight bullish momentum, and analysts have maintained a Buy rating despite recent adjustments due to the reverse stock split.
The company's financials are weak, with no revenue growth, a significant net income loss (-$26.86M), and declining EPS (-12.10% YoY). There is no recent news, no significant hedge fund or insider activity, and no recent congressional trading data. Additionally, the reverse stock split to maintain NASDAQ listing requirements signals potential challenges.
In Q3 2025, Adicet Bio reported no revenue growth (0% YoY), a net income loss of -$26.86M (-11.88% YoY), and a declining EPS of -4.72 (-12.10% YoY). Gross margin remains at 0%.
Analysts have maintained a Buy rating. H.C. Wainwright raised the price target to $50 from $9, citing the reverse stock split. Canaccord adjusted the price target to $18 from $128 due to the same reverse split. These changes reflect technical adjustments rather than fundamental improvements.
